ZBD announced that its wholly-owned subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The notice approves the change of the marketing authorization holders for 10 drugs, including Olanzapine Tablets, Apixaban Tablets, Escitalopram Oxalate Tablets, Desloratadine Tablets, Voriconazole Tablets, Mecobalamin Tablets, Rivaroxaban Tablets, Valsartan Tablets, and Donepezil Hydrochloride Tablets, from Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to Harbin Zhenbao Pharmaceutical Co., Ltd. The above matters will not have a significant impact on the company's current operating performance